单位:[1]Department of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China[2]Department of Rheumatology, China-Japan Friendship Hospital, Beijing 100029, China[3]Department of Radiology, China-Japan Friendship Hospital, Beijing, China
Objective To analyze the clinical features and outcomes of the patients with anti-glycyl tRNA synthetase (anti-EJ) syndrome in a large Chinese cohort. Methods The medical records, imaging, and serologic data of patients with anti-EJ antibodies from the China-Japan Friendship Hospital database were retrospectively investigated. Anti-EJ antibodies were identified using immunoblot assay. Long-term follow-up was conducted. Results Anti-EJ antibodies were present in 46 (19.7%) of the 234 patients with antisynthetase syndrome (ASS), preceded by anti-Jo-1 and anti-PL-7 antibodies. The mean age of disease onset was 51.2 +/- 15.9 years, and 69.6% of these patients were female. The most prevalent clinical feature was interstitial lung disease (ILD) (96.7%), which was also the most common initial manifestation, followed by fever (60.9%), mechanic's hands (56.5%), muscle involvement (50%), and Raynaud phenomenon (8.7%). Ten (21.7%) patients developed rapidly progressive ILD (RP-ILD). Organizing pneumonia (OP) on high-resolution computed tomography (HRCT) scans (OR = 37.5,p = 0.006) and a higher C-reactive protein-to-albumin ratio (CAR) (OR = 28.3,p = 0.01) were independent risk factors for RP-ILD. Muscular pathological features were heterogeneous. Concomitant infection was noted in 63.0% of the patients during the disease course. Hypoalbuminemia (OR = 0.759,p = 0.002) was an independent risk factor for concomitant infection. Patients responded well to glucocorticoid therapy. The 5- and 10-year survival rates of the patients with anti-EJ were 97.8% and 88%, respectively. Conclusion Anti-EJ syndrome was found to be a relatively common ASS subtype, with a favorable outcome. A notable proportion of the patients experienced RP-ILD, which was prone to OP on HRCT and a higher CAR, and needed aggressive management.
基金:
Beijing Municipal Science and Technology CommissionBeijing Municipal Science & Technology Commission [Z181100001718063, Z171100001017208] Funding Source: Medline; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571603] Funding Source: Medline
第一作者单位:[1]Department of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
通讯作者:
推荐引用方式(GB/T 7714):
Yinli Zhang,Yongpeng Ge,Hanbo Yang,et al.Clinical features and outcomes of the patients with anti-glycyl tRNA synthetase syndrome[J].CLINICAL RHEUMATOLOGY.2020,39(8):2417-2424.doi:10.1007/s10067-020-04979-8.
APA:
Yinli Zhang,Yongpeng Ge,Hanbo Yang,He Chen,Xiaolan Tian...&Guochun Wang.(2020).Clinical features and outcomes of the patients with anti-glycyl tRNA synthetase syndrome.CLINICAL RHEUMATOLOGY,39,(8)
MLA:
Yinli Zhang,et al."Clinical features and outcomes of the patients with anti-glycyl tRNA synthetase syndrome".CLINICAL RHEUMATOLOGY 39..8(2020):2417-2424